A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria:

- Diagnosis of relapsing/refractory or previously untreated CLL

- Eastern Cooperative Oncology Group (ECOG) performance score of less than equal to
(
- Adequate bone marrow function

- Adequate coagulation, renal and hepatic function

- Hematological values within the limits independent of growth factor support or
transfusion unless cytopenia is caused by the underlying disease, i.e., no evidence of
additional bone marrow dysfunction (e.g., myelodysplastic syndrome, hypoplastic bone
marrow)

Exclusion Criteria:

- Participants received an allogeneic stem cell transplant

- Known human immunodeficiency virus (HIV) positivity

- Uncontrolled autoimmune hemolytic anemia or thrombocytopenia

- Positive test results for chronic hepatitis B infection and hepatitis C virus (HCV)

- Received any anti-cancer therapy including chemotherapy or radiotherapy, steroid
therapy for anti-neoplastic intent, and investigational therapy, including targeted
small molecule agents within 28 days prior to the first dose of study drug or has not
recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(s) of
the previous therapy

- Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic,
immunologic, cardiovascular, or hepatic disease